170 related articles for article (PubMed ID: 35487690)
1. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
[TBL] [Abstract][Full Text] [Related]
3. [Experience of Pembrolizumab Administration in A Patient with Castration-Resistant Microsatellite Instability-High Prostate Cancer].
Takasawa T; Amano T; Himeno M; Imao T
Hinyokika Kiyo; 2024 Feb; 70(2):51-54. PubMed ID: 38447945
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
5. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE; Lai M; Yu EY; Schweizer MT
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
[TBL] [Abstract][Full Text] [Related]
6. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
7. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.
Fujiwara M; Komai Y; Yuasa T; Numao N; Yamamoto S; Fukui I; Yonese J
IJU Case Rep; 2020 Mar; 3(2):62-64. PubMed ID: 32743472
[TBL] [Abstract][Full Text] [Related]
10. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
[TBL] [Abstract][Full Text] [Related]
12. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.
Kageyama T; Soga N; Sekito S; Kato S; Ogura Y; Kojima T; Kanai M; Inoue T
IJU Case Rep; 2022 Nov; 5(6):442-445. PubMed ID: 36341181
[TBL] [Abstract][Full Text] [Related]
14. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Pritchard CC; Morrissey C; Kumar A; Zhang X; Smith C; Coleman I; Salipante SJ; Milbank J; Yu M; Grady WM; Tait JF; Corey E; Vessella RL; Walsh T; Shendure J; Nelson PS
Nat Commun; 2014 Sep; 5():4988. PubMed ID: 25255306
[TBL] [Abstract][Full Text] [Related]
15. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.
Yoshida T; Yaegashi H; Toriumi R; Kadomoto S; Iwamoto H; Izumi K; Kadono Y; Ikeda H; Mizokami A
Front Oncol; 2022; 12():912490. PubMed ID: 36185251
[TBL] [Abstract][Full Text] [Related]
16. Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability.
Kets CM; van Krieken JH; Hebeda KM; Wezenberg SJ; Goossens M; Brunner HG; Ligtenberg MJ; Hoogerbrugge N
Br J Cancer; 2006 Dec; 95(12):1678-82. PubMed ID: 17117178
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
19. Testing for Microsatellite Instability in Colorectal Cancer - a Comparative Evaluation of Immunohistochemical and Molecular Methods.
Vg DR; Nayanar SK; Gopinath V; Philip KJ; Aryadan N; Nair V; Perumal V
Gulf J Oncolog; 2022 May; 1(39):70-78. PubMed ID: 35695349
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
